Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TILC

Financiado

Targeting Innate Lymphoid Cells

TILC focuses on Innate Lymphoid Cells (ILCs). ILCs are a newly discovered type of lymphocyte, and their study opens up new perspectives for understanding and manipulating of immunity. ILCs include cytotoxic ILCs (NK cells) and hel... ver más

31/12/2022

AMU

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

UNIVERSITE DAIX MARSEILLE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-12-31

ERC-ADG-2015: ERC Advanced Grant

I+D

Cerrada hace 9 años

0% 100% 100%

3 Participantes

AMU

2.50M€ | Lider

SEMIC, S.A.

222.87K€ | Participante

APHM

242.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ActSwiftly Activation and switch of fates in T lymphocytes. 3M€ Cerrado

ILCADAPT Innate lymphoid cells and tissue adaptation to changing meta... 2M€ Cerrado

RegNK Regulation of NK cell function 2M€ Cerrado

SAF2016-79040-R CARACTERIZACION FUNCIONAL DE LA REGULACION DE LA INMUNIDAD I... 351K€ Cerrado

SAF2012-39536 FUNCION DE LA MOLECULA CD229 (LY9), UN MIEMBRO DE LA FAMILA... 145K€ Cerrado

SAF2009-09711 ALTERACIONES FENOTIPICAS Y FUNCIONALES DE LAS CELULAS NK EN... 121K€ Cerrado

Duración del proyecto: 73 meses Fecha Inicio: 2016-11-21
Fecha Fin: 2022-12-31

Líder del proyecto

UNIVERSITE DAIX MARSEILLE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto TILC focuses on Innate Lymphoid Cells (ILCs). ILCs are a newly discovered type of lymphocyte, and their study opens up new perspectives for understanding and manipulating of immunity. ILCs include cytotoxic ILCs (NK cells) and helper-like ILCs (ILC1, ILC2 & ILC3). Studies of ILC2 cells have advanced considerably, but much remains unknown about the respective roles of NK, ILC1 and ILC3 cells. TILC aims to explore new frontiers in ILC biology, by focusing on these subsets of ILCs in mice and humans, through five specific aims. 1. NK cells, ILC1 & NCR+ILC3 are known to express NKp46 in humans and mice, but the nature of the NKp46 ligands remains unclear, limiting our understanding of the biology of these three major ILC subsets. We thus aim to identify the NKp46 ligands, building on our preliminary data showing that Complement Factor P (CFP, Properdin) is involved in NKp46 recognition, hence revealing an unprecedented mode of immune recognition. 2. We also aim to create new mouse models selectively targeting these ILC subsets in vivo. We will then use these models for dissecting out the selective roles of ILC subsets in two major immune functions: cancer surveillance and gut homeostasis. 3. In cancer, we will investigate the contribution of these cells to tumor editing. 4. In the intestine, we will focus on the homeostasis of the cecum and appendix. These organs were long considered to be vestiges of evolution, but our own recent findings and those of phylogenetic studies have challenged this notion. We thus aim to address the role of ILC subsets in the cecum/appendix, and determine whether these organs serve as a refuge for repopulation with commensals after dysbiosis. 5. Finally, we aim to identify patients with deficiencies in ILCs, to dissect the function of these cells in natura. From the molecular scale to that of patients, we believe that TILC will provide answers to some of the most pressing questions concerning the role and clinical potential of NKp46+ ILCs

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores